Neurology
Alzheimer's Disease (AD)
1
Pipeline Programs↗
7
Active Trials↗
7
Companies Involved↗
Alzheimer's Disease (AD) is an early-stage landscape with 1 program across 7 companies. The most active players are Roche, Eli Lilly, EIP Pharma Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
29
clinical trials
Completed13 · 45%
Terminated7 · 24%
Active, not recruiting3 · 10%
Recruiting3 · 10%
Withdrawn1 · 3%
Unknown status1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
29 trials
The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
Recruiting·Stichting International Registry for Alzheimer's Disease and other Dementias Foundation·N/A·NCT07213700·50,000 enrolled
Effect and Safety of Non-invasive Electrical Stimulation in Improving Cognitive and Depressive Symptoms in Alzheimer's Disease
Enrolling by invitation·FFirst Affiliated Hospital of Zhejiang University·Preclinical·NCT07694921·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)